# RD SYSTEMS a biotechne brand

**Recombinant Human/Mouse/Rat BMP-2** 

Catalog Number: 355-BM

DESCRIPTION	
Source	Chinese Hamster Ovary cell line, CHO-derived BMP-2 protein Gln283-Arg396 Accession # P12643
Structure / Form	Disulfide-linked homodimer
Predicted Molecular	13 kDa (monomer)

SPECIFICATIONS	
SDS-PAGE	15-16 kDa, reducing conditions
Activity	Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Binnerts, M.E. <i>et al.</i> (2004) Biochem. Biophys. Res. Commun. <b>315(2)</b> :272. The ED <sub>50</sub> for this effect is 40-200 ng/mL. The specific activity of Recombinant Human BMP-2 is approximately 781 U/µg, which is calibrated against human BMP-2 WHO International Standard (NIBSC code: 93/574). Specific activity is for reference purposes only and is not routinely tested.
Endotoxin Level	<0.10 EU per 1 $\mu$ g of the protein by the LAL method.
Purity	>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 µm filtered solution in Glycine, Sucrose, Tween® 80 and Glutamic Acid with BSA as a carrier protein. *1 mg pack size (01M) is supplied as a 0.2 µm filtered solution in Glycine, Sucrose, Tween® 80 and Glutamic Acid with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 100-200 µg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.	
	<ul> <li>12 months from date of receipt, -20 to -70 °C as supplied.</li> </ul>	
	1 month, 2 to 8 °C under sterile conditions after reconstitution.	

3 months, -20 to -70 °C under sterile conditions after reconstitution.



#### Bioactivity of Human/Mouse/Rat BMP-2 Protein Recombinant human/mouse/rat BMP-2 (Catalog # 355-BM) induces alkaline phosphatase production in the ATDC5 mouse chondrogenic cell line. The ED<sub>50</sub> for this effect is 40-200 ng/mL.

Rev. 5/25/2021 Page 1 of 2



**Global** bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



## Recombinant Human/Mouse/Rat BMP-2

Catalog Number: 355-BM

### BACKGROUND

Bone morphogenetic protein 2 (BMP-2) is a member of the BMP subgroup of the TGF-β superfamily. It plays a dominant role in embryonic dorsal-ventral patterning, organogenesis, limb bud formation, and bone formation and regeneration (1, 2). Human BMP-2 is synthesized as a 396 amino acid (aa) preproprotein that contains a 23 aa signal sequence, a 259 aa prosegment, and a 114 aa mature region (3). Proteolytic removal of the propeptide enables mature BMP-2 to form active disulfide linked homodimers and heterodimers with BMP-7 (2). Mature monomeric BMP-2 is an 18 kDa glycosylated peptide with seven conserved cysteines that form a cystine knot structure (4). Mature human BMP-2 shares 100% aa sequence identity with mouse and rat BMP-2. It shares 85% aa sequence identity with human BMP-4 and less than 51% with other BMPs. BMP-2 signals through heterodimeric complexes composed of a type I receptor (Activin RI, BMPR-IA) and a type II receptor (BMP RII or Activin RIIB) (2, 5). BMP-2 induces chondrocyte proliferation, endochondral bone formation, longitudinal bone growth, and bone and cartilage repair (6, 7). It induces ectopic bone formation or calcification by promoting osteogenic and chondrogenic differentiation in mesenchymal cells, stem cells, and vascular smooth muscle cells (2, 8-10). BMP-2/BMP-7 heterodimers are significantly more potent than BMP-2 homodimers at inducing bone formation *in vivo* (11). BMP-2 also promotes the maintenance and repair of colonic epithelium, suppresses neuronal dopamine synthesis and release, induces apoptosis in medulloblastoma cells, and is required for cardiac contractility (12-15).

#### References:

- 1. Kishigami, S. and Y. Mishina (2005) Cytokine Growth Factor Rev. 16:265.
- 2. Chen, D. et al. (2004) Growth Factors 22:233.
- 3. Wozney, J. et al. (1988) Science 242:1528.
- 4. Sun, P.D. and D.R. Davies (1995) Annu. Rev. Biophys. Biomol. Struct. 24:269.
- 5. Sebald, W. *et al.* (2004) Biol. Chem. **385**:697.
- 6. De Luca, F. et al. (2001) Endocrinology 142:430.
- 7. Davidson, E.N.B., et al. (2007) Arthritis Res. Ther. 9:R102.
- 8. Ryoo, H.-M. et al. (2006) Gene 366:51.
- 9. Kramer, J. et al. (2000) Mech. Dev. 92:193.
- 10. Li, X. et al. (2008) Atherosclerosis January 5 epub.
- 11. Zhu, W. et al. (2004) J. Bone Miner. Res. 19:2021.
- 12. Peiris, D. et al. (2007) Am. J. Physiol. Gastrointest. Liver Physiol. 292:G753.
- 13. Kano, Y. et al. (2005) Endocrinology 146:5332.
- 14. Hallahan, A.R. et al. (2003) Nat. Med. 9:1033.
- 15. Wang, Y.-X. et al. (2007) Cardiovasc. Res. 74:290.

Rev. 5/25/2021 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449